Abstract 69P
Background
Colorectal cancer is one of the commonest malignancies worldwide. Next Generation Sequencing (NGS) helps inform treatment pathways for patients post surgery, and also provides valuable information regarding genetic mutations in cancer, the pathogenesis and biology of the disease. We reviewed NGS mutation profiling in our colorectal cancer patients.
Methods
NGS analysis was performed over a 7 year period. Data retrieved from medical records and pathology reports.
Results
92 patients underwent surgery for colorectal cancer during the study period. Mean age: 71 years (Range:44-87). M:F: 1.05:1 43 patients (46.7%) were found to have mutations on NGS sequencing. No significant difference in age, sex, tumour size, lymph node ratio or stage at presentation between the two groups. NGS mutation was significantly associated with right sided disease (p=0.01, Fishers exact test), and this association was highly significant for the BRAF V600e mutation (p=0.0001), NGS mutation was significantly associated with mucinous disease (p=0.04), lymphovascular and / or perineural invasion (p=0.02), and microsatellite instability (p=0.0136), but not metastatic disease at presentation (p=1). Kaplan Meier survival analysis revealed no difference in survival between patients with NGS mutations and those without (p=0.52) or on any subset analysis. COX proportional hazards testing revealed only a significant relationship between tumour size and survival in all patients on multivariate analysis (p=0.002).
Conclusions
NGS sequencing provides relevant information regarding the association of cancers with aggressive features and microsatellite instability. Association of the BRAF mutation with right sided colon cancers has been described previously and may reflect a different pathway to carcinogenesis in the right colon, which has been postulated to have a different origin to the left colon. Significant association of gene mutations with microsatellite instability, but no difference in metastatic disease and overall survival may relect better immune response to these tumours, MSI has been observed to be associated with reduced risk of metastasis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
105P - Subsequent treatments after progression on cyclin-dependent kinase 4/6 inhibitors: A multicentric real-world data study
Presenter: Ana Rita Freitas
Session: Cocktail & Poster Display session
Resources:
Abstract
106P - Toxicity profile antibody-drug conjugates (ADCs) in metastatic breast cancer patients: A systematic review and meta-analysis based on studies’ design
Presenter: Silvia Belloni
Session: Cocktail & Poster Display session
Resources:
Abstract
107P - Receptor change on residual disease following neoadjuvant therapies for locally advanced breast cancer fails to impact oncological and survival outcomes
Presenter: Rionagh Lynch
Session: Cocktail & Poster Display session
Resources:
Abstract
114P - Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAFV600E wild type metastatic colorectal cancer in the CAPRI 2-GOIM trial
Presenter: Davide Ciardiello
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - Impact of tissue factor on clinical and biological characteristics in patients with advanced pancreatic cancer
Presenter: Taro Shibuki
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Multiomic profiling based on <italic>Akkermansia muciniphila</italic> in advanced non-small cell lung cancer
Presenter: Lorenzo Belluomini
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Transforming public patient omic data into precision oncology targets: A comprehensive pan-cancer approach
Presenter: Eléonore Fox
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Whole transcriptome sequencing of lung tissue to combine disease classification and identification of actionable targets
Presenter: Alejandro Pallares Robles
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - Genetic profiling of breast cancer in a developing country: Towards the establishment of oncogenetics in Cameroon
Presenter: Kenn Chi Ndi
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Uncovering the prognostic potential of FGFR2c isoform expression in advanced gastroesophageal cancer through MONSTAR-SCREEN-2 analysis
Presenter: Tadayoshi Hashimoto
Session: Cocktail & Poster Display session
Resources:
Abstract